Search by drug, manufacturer, or indication

Displaying 1031 - 1040 of 1165

Jardiance (empagliflozin)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Diabetes Mellitus, Type 2 with high cardiovascular risk

Last updated April 13, 2016

Trajenta/Jentaduo (linagliptin (linagliptin/metformin))

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Diabetes Mellitus, Type 2

Last updated April 12, 2016

Prezcobix (darunavir/cobicistat)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

HIV-1 Infection

Last updated March 24, 2016

Daklinza (daclatasvir)

Status:

Concluded without agreement

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Chronic Hepatitis C

Last updated March 17, 2016

Inspiolto Respimat (tiotropium/olodaterol)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Heart failure, NYHA class II

Last updated March 2, 2016

Spiriva Respimat (tiotropium bromide)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated March 2, 2016

Zaxine (rifaximin)

Status:

Concluded with an LOI

Manufacturer:

Lupin Pharma Canada Ltd.

Indication:

Hepatic Encephalopathy

Last updated March 2, 2016

Soliris (eculizumab)

Status:

Concluded without agreement

Manufacturer:

Alexion Pharma Canada Corp.

Indication:

Atypical hemolytic uremic syndrome

Last updated February 16, 2016

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Metastatic Melanoma

Last updated February 10, 2016

Januvia (sitagliptin phosphate)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated February 8, 2016